Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inotek Pharmaceuticals Corp.

Division of Rocket Pharmaceuticals Inc.
www.inotekpharma.com

Latest From Inotek Pharmaceuticals Corp.

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend

Moderna raised $500m to fund its growing pipeline, choosing once again to stay private rather than pursue an IPO. Also, AvroBio closed a $60m Series B round to advance its gene therapies for lysosomal storage disorders, Seattle Genetics led recent public company financings, and Vical is restructuring.

Financing Business Strategies

Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash

Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.

StartUps and SMEs Financing

Appointments: Flex Pharma, Bicycle Therapeutics, Nordic Nanovector, Biogen, CRISPR and NightstaRx

The week's roundup includes the appointment of a new CEO by Flex Pharma and various other high-level appointments by Bicycle Therapeutics, SetPoint Medical, Theravance Biopharma and Nordic Nanovector.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rocket Pharmaceuticals Inc.
  • Senior Management
  • David P Southwell, Pres. & CEO
    Rudolph A Baumgartner, MD, EVP, CMO
    Dale Ritter, VP, Fin.
    William K McVicar, PhD, EVP, CSO
    Claudine Prowse, PhD, VP, Strategy & Investor Relations
  • Contact Info
  • Inotek Pharmaceuticals Corp.
    Phone: (781) 676-2100
    91 Hartwell Ave., 2nd Fl.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register